SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2013 / Cilt: 22 - Sayı: 3

Son dönem böbrek yetersizlikli hastalarda prohepsidin ve kardiyovasküler risk belirteçleri arasındaki ilişki

Relationship between prohepcidin and cardiovascular risk markers in end stage renal failure patients

İbrahim DOĞAN
Mehmet Ali EREN
Serdar KAHVECİOĞLU
Yasemin ÜSTÜNDAĞ
Mahmut ARABUL
Aysel KADERLİ
Türker EMRE
Mustafa GÜLLÜLÜ
Emre SARANDOL
Pages
290–296
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Prohepcidin level was significantly associated with CC concentration (β=0.855, R2=0.73, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The leading cause of death in patients with end-stage renal disease (ESRD) is cardiovascular disease.
📊
Key Findings & Data:MATERIAL and METHODS: Twenty-two chronic hemodialysis patients, 21 chronic peritoneal dialysis patients, and 16 healthy controls were included in the present study.
💡
Conclusion & Impact:Prohepcidin level was significantly associated with CC concentration (β=0.855, R2=0.73, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The leading cause of death in patients with end-stage renal disease (ESRD) is cardiovascular disease. Prohepcidin, which is the precursor of hepcidin is a peptide hormone produced by the liver, and appears to be the master regulator of iron homeostasis in humans. High prohepcidin levels may contribute to progression of cardiovascular disease in end-stage renal insufficiency patients. However, any such association remains poorly understood. The purpose of the present study was to investigate the relationship between prohepcidin and cardiovascular risk markers in end-stage renal failure patients. MATERIAL and METHODS: Twenty-two chronic hemodialysis patients, 21 chronic peritoneal dialysis patients, and 16 healthy controls were included in the present study. The levels of serum prohepcidin (the precursor form of hepcidin), high sensitivity C-reactive protein (hs-CRP), troponin-T (TT), and cystatin C (CC) were determined using commercial kits. The left ventricular mass index (LVMI) was estimated using echocardiography. RESULTS: The levels of the CVD risk markers TT, CC, and prohepcidin differed, with statistical significance, between the patient and control groups. Prohepcidin level was significantly associated with CC concentration (β=0.855, R2=0.73, p

Özet

AMAÇ: Hepsidinin öncül molekülü olan prohepsidin karaciğerden yapılan bir peptit hormon olup demir metabolizmasının ana düzenleyicisidir. Son dönem böbrek yetersizlikli hastalarda yüksek prohepsidin seviyelerinin kardiyovasküler hastalıklarla ilişkili olabileceği düşünülmektedir. Ancak bu ilişki net bir şekilde anlaşılamamıştır. Bu çalışmadaki amacımız, SDBYli hastalarda prohepsidin ile kardiyovasküler risk belirteçleri arasında ilişkiyi araştırmaktır. GEREÇ ve YÖNTEMLER: Çalışmaya 22 kronik hemodiyaliz, 21 kronik periton diyaliz hastası ile birlikte 16 sağlıklı kontrol dahil edildi. Rutin laboratuvar tetkiklerine ilave olarak hastalardan prohepsidin, yüksek hassasiyetli C reaktif protein (hsCRP), troponin T (TT) ve sistatin C (CC) değerleri ölçüldü. Ekokardiyografi ile sol ventrikül kitle indeksleri (LVMI) belirlendi. BULGULAR: Hastaların olduğu gruplarda ölçülen prohepsidin, TT, CC yüksekliği kontrol grubuna göre istatistiksel olarak anlamlıydı. Ayrıca prohepsidin CC (β=0,855, R2=0,73, p

🔖

Cite This Article

DOĞAN, İ., EREN, M. A., KAHVECİOĞLU, S., ÜSTÜNDAĞ, Y., ARABUL, M., KADERLİ, A., EMRE, T., GÜLLÜLÜ, M., SARANDOL, E. (2022). Son dönem böbrek yetersizlikli hastalarda prohepsidin ve kardiyovasküler risk belirteçleri arasındaki ilişki. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 22 - Sayı: 3, 290–296. https://ajindex.com/articles/655005

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Thijssen S, Usvyat L, Kotanko P: Prediction of mortality in the first two years of hemodialysis: Results from a validation study. Blood Purif 2012; 33: 165-170
  2. Akdag I, Yilmaz Y, Kahvecioglu S, Bolca N, Ercan I, Ersoy A, Gullulu M: Clinical value of the malnutrition–inflammation–atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study. Nephron Clin Pract 2008; 108: 99-105
  3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214- 2219 Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
  4. Cohen LM, Ruthazer R, Moss AH, Germain MJ: Predicting six- month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol 2010; 5: 72-79
  5. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loréal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin is overexpressed during iron overload. J Biol Chem 2001; 276(11): 7811-7819
  6. Vyoral D, Petrak J. Hepcidin: A direct link between iron metabolism and immunity. Int J Biochem Cell Biol 2005; 37(9): 1768-1773 Détivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, Ropert M, Jacquelinet S, Courselaud B, Ganz T, Brissot P, Loréal O: Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005; 106(2): 746-748
  7. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chemc 2001; 276: 7806-7810 Sullivan JL: Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007; 232: 1014-1020
  8. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99(7): 4596-4601
  9. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102: 1906-1910
  10. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with L